Ciliation Index Is a Useful Diagnostic Tool in Challenging Spitzoid Melanocytic Neoplasms.
Adolescent
Adult
Aged
Aged, 80 and over
Algorithms
Biomarkers, Tumor
/ metabolism
Child
Child, Preschool
Cilia
/ metabolism
Comparative Genomic Hybridization
Diagnosis, Differential
False Positive Reactions
Female
Humans
Machine Learning
Male
Melanocytes
/ pathology
Melanoma
/ diagnosis
Middle Aged
Nevus, Epithelioid and Spindle Cell
/ diagnosis
Predictive Value of Tests
Skin Neoplasms
/ diagnosis
Young Adult
Melanoma, Cutaneous Malignant
Journal
The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
11
07
2019
revised:
08
11
2019
accepted:
27
11
2019
pubmed:
25
1
2020
medline:
3
3
2021
entrez:
25
1
2020
Statut:
ppublish
Résumé
The loss of primary cilia on melanocytes is a useful biomarker for the distinction of melanoma from conventional melanocytic nevi. It is unknown whether ciliation status is beneficial for diagnosing spitzoid tumors-a subclass of melanomas that present inherently ambiguous histology and are challenging to classify. We evaluated the Ciliation Index (CI) in 68 cases of spitzoid tumors ranging from Spitz nevi and atypical Spitz tumors to spitzoid melanoma. We found a significant decrease in CI within the spitzoid melanoma group when compared with either the Spitz nevi or atypical Spitz tumors groups. In addition, we used a machine-learning-based algorithm to determine the value of CI when considered in combination with other histopathologic and molecular features commonly used for diagnosis. We found that a low CI was consistently ranked as a top predictive feature in the diagnosis of malignancy. Predictive models trained on only the top four predictive features (CI, asymmetry, hyperchromatism, and cytologic atypia) outperformed standard histologic assessment in an independent validation cohort of 56 additional cases. The results provide an alternative approach to evaluate diagnostically challenging melanocytic lesions, and further support the use of CI as an ancillary diagnostic test.
Identifiants
pubmed: 31978411
pii: S0022-202X(20)30038-5
doi: 10.1016/j.jid.2019.11.028
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1401-1409.e2Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.